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Corneal confocal microscopy 
identifies small fibre damage 
and progression of diabetic 
neuropathy
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Accurately quantifying the progression of diabetic peripheral neuropathy is key to identify individuals 
who will progress to foot ulceration and to power clinical intervention trials. We have undertaken 
detailed neuropathy phenotyping to assess the longitudinal utility of different measures of 
neuropathy in patients with diabetes. Nineteen patients with diabetes (age 52.5 ± 14.7 years, duration 
of diabetes 26.0 ± 13.8 years) and 19 healthy controls underwent assessment of symptoms and signs 
of neuropathy, quantitative sensory testing, autonomic nerve function, neurophysiology, intra-
epidermal nerve fibre density (IENFD) and corneal confocal microscopy (CCM) to quantify corneal 
nerve fibre density (CNFD), branch density (CNBD) and fibre length (CNFL). Mean follow-up was 
6.5 years. Glycated haemoglobin (p = 0.04), low-density lipoprotein-cholesterol (LDL-C) (p = 0.0009) 
and urinary albumin creatinine ratio (p < 0.0001) improved. Neuropathy symptom profile (p = 0.03), 
neuropathy disability score (p = 0.04), vibration perception threshold (p = 0.02), cold perception 
threshold (p = 0.006), CNFD (p = 0.03), CNBD (p < 0.0001), CNFL (p < 0.0001), IENFD (p = 0.04), sural 
(p = 0.02) and peroneal motor nerve conduction velocity (p = 0.03) deteriorated significantly. Change 
(∆) in CNFL correlated with ∆CPT (p = 0.006) and ∆Expiration/Inspiration ratio (p = 0.002) and 
∆IENFD correlated with ∆CNFD (p = 0.005), ∆CNBD (p = 0.02) and ∆CNFL (p = 0.01). This study shows 
worsening of diabetic neuropathy across a range of neuropathy measures, especially CCM, despite 
an improvement in HbA1c and LDL-C. It further supports the utility of CCM as a rapid, non-invasive 
surrogate measure of diabetic neuropathy.
The natural history of diabetic peripheral neuropathy (DPN) is poorly defined with limited studies assessing pro-
gression of  neuropathy1. As a consequence, clinical trials of disease modifying therapies in patients with diabetic 
neuropathy have not been able to identify the optimal neuropathy end points to adequately assess progression 
or improvement in  DPN2. Indeed, whilst the DCCT in patients with T1DM showed that intensive glycaemic 
control reduced the incidence of clinical DPN and nerve conduction abnormalities by 60%3; in patients with 
T2DM, the  UKPDS4 and VA-CSDM  trial5 reported no effect on DPN and cardiac autonomic neuropathy and 
whilst the Kumamoto  study6 showed a prevention of nerve conduction slowing, the ACCORD  trial7 showed no 
effect on VPT over 6-years.
Quantitative sensory testing (QST) is relatively easy to perform but has limited reproducibility and a high 
degree of  subjectivity8. Nerve conduction studies (NCS) are the established ‘gold standard’ for evaluating DPN 
but require standardization in a clinical trial and cannot evaluate small  fibres9. Whilst small nerve fibre damage 
and repair can be identified by performing a skin biopsy and quantifying intra-epidermal nerve fibre density 
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(IENFD), it is invasive and requires  expertise10–12. Other techniques for the assessment of small nerve fibres 
include microneurography, Laser doppler image flare (LDIflare), nociceptive-evoked potentials and electro-
chemical skin conductance, but have considerable variability and are not routinely  available13,14. Corneal confo-
cal microscopy (CCM) is a rapid non-invasive imaging technique for the quantitative assessment of small fibre 
damage. Several studies have shown that it has good diagnostic utility for sub-clinical DPN, predicts incident 
 DPN15,16 and correlates with other measures of  neuropathy16. Furthermore, automated quantification of corneal 
nerve parameters allows rapid, unbiased and objective assessment of small fibre  damage17 with comparable 
diagnostic capability to  IENFD18,19.
Longitudinal studies of patients with diabetic neuropathy have been of relatively short duration and lacked 
detailed neuropathy  phenotyping20–23. In this study we compare the change in CCM and IENFD with symptoms, 
signs, QST, autonomic function and neurophysiology over 6.5 years in a cohort of patients with diabetes.
Results
Clinical and metabolic assessment (Tables 1, 2). Age (p = 0.2), weight (p = 0.9) and body mass index 
(BMI) (p = 0.5) did not differ significantly between patients and controls and also between patients at baseline 
and follow up. Systolic (p = 0.9, p = 0.37) and diastolic (p = 0.5, p = 0.08) blood pressure did not differ between 
controls and patients at baseline and between patients at baseline and follow up, respectively. HbA1c was signifi-
cantly higher in patients with diabetes compared to controls at baseline (p = 0.0002) and decreased significantly 
in patients at follow up (p = 0.04). Low density lipoprotein cholesterol (LDL-C) was significantly lower in dia-
betic patients compared to controls at baseline (p = 0.05) and decreased further at follow up (p = 0.0009), whilst 
triglycerides did not differ between patients and controls at baseline (p = 0.9) and did not change at follow up 
(p = 0.9). eGFR did not differ significantly between diabetic patients and controls at baseline and decreased at 
follow up (p = 0.004). Albumin creatinine ratio (ACR) was significantly higher in diabetic patients compared to 
controls at baseline (p < 0.0001) and increased further at follow up (p < 0.0001).
Neuropathy assessments. Neuropathic symptoms and deficits (Tables 1, 2, Fig. 3). Neuropathy symp-
tom profile (NSP) (p = 0.0005) and neuropathy disability score (NDS) (p < 0.0001) were significantly higher in 
patients at baseline compared to controls and increased significantly (p = 0.03, p = 0.04, respectively) in patients 
at follow up.
Quantitative sensory testing (QST) (Tables 1, 2, Fig. 3). Vibration perception threshold (VPT), cold perception 
threshold (CPT), warm perception threshold (WPT), cold induced pain (CIP), warm induced pain (WIP) and 
percentage colour change in Neuropad did not differ significantly (p > 0.05) in patients at baseline compared to 
controls. Whilst VPT increased (p = 0.02) and CPT (p = 0.006) decreased significantly there was no change in 
WPT, CIP, WIP and Neuropad.
Electrophysiology (Tables 1, 2, Fig. 3). Sural (p = 0.01) and peroneal (p = 0.007) nerve conduction velocity and 
peroneal nerve amplitude (p = 0.004) were significantly lower in patients at baseline compared to controls. Sural 
(p = 0.02) and peroneal (p = 0.03) nerve conduction velocity decreased significantly, with no change in sural 
(p = 0.75) or peroneal (p = 0.29) nerve amplitudes in patients at follow up.
Autonomic neuropathy (Tables 1, 2, Fig. 3). Deep breathing heart rate variability (DB-HRV) was significantly 
lower in patients at baseline compared to controls (p = 0.005). Expiration/inspiration (E/I) ratio (p = 0.004), Val-
salva ratio (p = 0.001), and 30:15 ratio (p = 0.003) increased significantly with no change in DB-HRV (p = 0.67) 
and sympathetic low frequency area (LFa)/parasympathetic respiratory frequency area (RFa) ratio (p = 0.42) at 
follow up.
IENFD (Tables  1, 2, Figs.  1 and 3). Intraepidermal nerve fibre density (IENFD) was significantly lower in 
patients at baseline (p = 0.04) compared to controls and decreased (p = 0.04) in patients at follow up.
CCM (Tables 1, 2, Figs. 2 and 3). Corneal nerve fibre density (CNFD) (p < 0.0001), Corneal nerve branch den-
sity (CNBD) (p = 0.009) and Corneal nerve fibre length (CNFL) (p = 0.0007) were significantly lower in patients 
at baseline compared to controls and CNFD (p = 0.03), CNBD (p < 0.0001) and CNFL (p < 0.0001) decreased at 
follow up.
Associations between the change in clinical and neuropathy measures (Table 3, Fig. 3). ΔIENFD correlated with 
age (r =  − 0.56, p = 0.01), BMI (r =  − 0.47, p = 0.04), waist to hip ratio (r =  − 0.66, p = 0.001), ΔE/I ratio (r = 0.595, 
p = 0.0071) and ΔValsalva ratio (r = 0.59, p = 0.0078). ΔCNFD correlated with ΔVPT (r =  − 0.54, p = 0.03), 
ΔDBHRV (r = 0.55, p = 0.02) and ΔIENFD (r = 0.62, p = 0.005). ΔCNFL correlated with ΔCPT (r = 0.66, p = 0.006), 
ΔE/I ratio (r = 0.68, p = 0.002) and ΔIENFD (r = 0.56, p = 0.014). ΔCNBD correlated with ΔVPT (r =  − 0.55, 
p = 0.02) and ΔIENFD (r = 0.53, p = 0.02). There was no correlation between change in HbA1c, lipids and neuro-
physiological parameters with change in CCM or IENFD (Supplementary Table 1).
Discussion
In this study we show a progressive worsening of diabetic neuropathy in diabetic patients despite an improvement 
in HbA1c and LDL cholesterol, although there was no correlation between change in HbA1c, and LDL choles-
terol with change in any measure of neuropathy. In T1DM the DCCT showed that intensive glycaemic control 
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reduced the incidence of  DPN3. However, in patients with T2DM, the  UKPDS4, VA-CSDM  trial5 and  ACCORD7 
trials showed no effect of improved glycaemic control on DPN. A major problem in these clinical trials was the 
end points utilised to assess neuropathy including symptoms and signs of neuropathy and quantitative sensory 
testing, which were unable to accurately measure change in  neuropathy2.
Neurophysiology is considered to be the gold standard for the diagnosis of DPN and has been adopted as 
an endpoint in multiple clinical  trials9, but has failed to show a significant change in these  trials24. Indeed, our 
longitudinal data now shows a relatively small magnitude of reduction in peroneal and sural nerve conduction 
with no change in amplitudes over 6.5 years. It is therefore not surprising that most trials lasting 12–24 months 
show no change in neurophysiology.
Small fibre damage usually precedes large fibre damage and contributes to clinically meaningful end-points 
like painful diabetic neuropathy and foot ulceration due to altered skin blood flow and delayed wound  healing2. 
Skin biopsy with IENFD quantification is the current gold standard for the evaluation of small fibre  damage9 
and whilst it is reliable and reproducible it is invasive and resource-intensive11. CCM is a rapid, non-invasive and 
reproducible ophthalmic imaging technique which can be used to objectively quantify small fibre damage in a 
Table 1.  Clinical and neuropathy parameters in control subjects and patients at baseline. BMI—body mass 
index, BP—blood pressure, HbA1c—Glycosylated haemoglobin, eGFR—estimated glomerular filtration rate, 
ACR—albumin creatinine ratio, LDL-C—low density lipoprotein cholesterol, NSP—neuropathy symptom 
profile, NDS—neuropathy disability score, VPT—vibration perception threshold, DBHRV—deep breathing 
heart rate variability, sural nerve action potential (SNAP), Sural nerve conduction velocity (SNCV), Peroneal 
nerve amplitude (PNAP), Peroneal motor nerve conduction velocity (PMNCV), CNFD—corneal nerve fibre 
density, CNBD—corneal nerve branch density, CNFL—corneal nerve fibre length, IENFD—intraepidermal 
nerve fibre density. Data is presented as mean ± standard deviation (SD). Bold values show statistically 
significant results. Continuous variables were compared between controls and baseline patient visits using the 
paired t-test for normally distributed data and Wilcoxon matched-pairs signed rank test for non-normally 
distributed data.
Variable Controls (n = 19) Patients (Baseline) (n = 19) p value
Clinical and laboratory parameters
Age (years) 47.4 ± 14.2 52.5 ± 14.7 0.20
Duration of diabetes (years) NA 26.0 ± 13.8 NA
Weight (kg) 80.7 ± 18.0 82.0 ± 19.8 0.9
BMI (kg/m2) 27.5 ± 4.0 29.0 ± 5.7 0.50
BP (mmHg) 131 ± 23/74.0 ± 11.0 132 ± 21/ 71 ± 8 0.90/0.50
HbA1c (mmol/mol) 37.5 ± 3 63.5 ± 18.7 0.0002
Triglycerides (mmol/l) 1.4 ± 0.7 1.8 ± 1.7 0.9
LDL—C (mmol/l) 2.7 ± 0.9 2.23 ± 0.9 0.05
eGFR (ml min/ [1.73 m]2) 83 ± 7 82 ± 20 0.70
ACR (mg/mmol) 0.3 ± 0.1 7.5 ± 15.7 < 0.0001
Clinical neuropathy and QST measures
NSP (/38) 0.15 ± 0.5 3.5 ± 4.5 0.0005
NDS (/10) 0.57 ± 1.0 3.7 ± 2.4 < 0.0001
VPT (V) 7.5 ± 6.9 13.0 ± 8.0 0.06
CPT (°C) 28.4 ± 2.3 26.5 ± 3.5 0.51
WPT (°C) 36.9 ± 2.2 40.0 ± 3.7 0.20
CIP (°C) 9.0 ± 8.3 8.0 ± 8.5 0.90
WIP (°C) 45.0 ± 2.8 47.0 ± 2.5 0.15
Autonomic neuropathy measures
DB-HRV (beats/min) 30 ± 12 21 ± 15 0.005
Neuropad (%) 91.0 ± 21 62.4 ± 34 0.13
Nerve conduction studies
SNAP (µV) 17.9 ± 9.7 11.41 ± 10.9 0.06
SNCV (m/s) 49.8 ± 4.5 43.5 ± 9.0 0.01
PNAP (mV) 6.0 ± 2.2 3.8 ± 1.9 0.004
PMNCV (m/s) 48.7 ± 4.1 43.5 ± 3.6 0.0007
Corneal confocal microscopy
CNFD (no./mm2) 37.7 ± 6.5 28.8 ± 6.5 < 0.0001
CNBD (no./mm2) 96.5 ± 38.6 67.6 ± 30.2 0.009
CNFL (mm/mm2) 27.2 ± 3.4 22.2 ± 4.9 0.0007
Skin biopsy
IENFD (no./mm) 9.8 ± 3.8 6.6 ± 4.3 0.04
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range of peripheral  neuropathies15,25–29. We have previously shown comparable diagnostic utility of CCM and 
IENFD in diabetic  neuropathy19. Furthermore, in longitudinal studies reduced corneal nerve fibre length predicts 
incident  DPN30,31 and those at risk of developing  DPN32. Indeed, CCM has shown corneal nerve regeneration 
6 months after pancreas and kidney transplantation in T1DM with no change in quantitative sensory testing and 
an improvement in neuropathic symptoms and nerve conduction only after 24 and 36 months,  respectively21,33. 
A recent study from Japan showed that an improvement in glycaemic control, body weight and blood pressure in 
Table 2.  Clinical and neuropathy parameters in patients at baseline and follow up. BMI—body mass index, 
BP—blood pressure, HbA1c—glycosylated haemoglobin, e GFR—estimated glomerular filtration rate, ACR—
albumin creatinine ratio, LDL-C—low density lipoprotein cholesterol, NSP—neuropathy symptom profile, 
NDS—neuropathy disability score, VPT—vibration perception threshold, CPT—cold perception threshold, 
WPT—warm perception threshold, CIP—cold induced pain, WIP—warmth induced pain, DBHRV—deep 
breathing heart rate variability, LFa/RFa ratio—low frequency area (sympathetic) and respiratory frequency 
area (parasympathetic) ratio, E/I—expiration/inspiration ratio, Sural nerve action potential (SNAP), Sural 
nerve conduction velocity (SNCV), Peroneal nerve amplitude (PNAP), Peroneal motor nerve conduction 
velocity (PMNCV), CNFD—corneal nerve fibre density, CNBD—corneal nerve branch density, CNFL—
corneal nerve fibre length, IENFD—intraepidermal nerve fibre density. Data is presented as mean ± standard 
deviation (SD). Bold values show statistically significant results. Continuous variables were compared between 
baseline and follow up visits using the paired t-test for normally distributed data and Wilcoxon matched-pairs 
signed rank test for non-normally distributed data.
Variable Patients (Baseline) (n = 19) Patients (Follow up) (n = 19) p value
Clinical and laboratory parameters
Age (years) 52.5 ± 14.7 59.5 ± 15.6 NA
Duration of diabetes (years) 26.0 ± 13.8 32.5 ± 13.8 NA
Weight (kg) 82.0 ± 19.8 81.75 ± 18 0.49
BMI (kg/m2) 29.0 ± 5.7 28.7 ± 5.2 0.53
BP (mmHg) 132 ± 21/ 71 ± 8 127 ± 20 / 67 ± 9 0.37/0.08
HbA1c (mmol/mol) 63.5 ± 18.7 55.9 ± 12 0.04
Triglycerides (mmol/l) 1.8 ± 1.7 1.5 ± 1.1 0.9
LDL-C (mmol/l) 2.2 ± 0.9 1.9 ± 1.2 0.0009
eGFR (ml  min−1 [1.73 m]−2) 82 ± 20 69 ± 21 0.004
ACR (mg/mmol) 7.5 ± 15.7 41.3 ± 123.6 < 0.0001
Clinical neuropathy measures and QST
NSP (/38) 3.5 ± 4.5 5.5 ± 5.7 0.03
NDS (/10) 3.7 ± 2.4 4.7 ± 2.5 0.04
VPT (V) 13.0 ± 8.0 18.0 ± 9.0 0.02
CPT (°C) 26.5 ± 3.5 21.8 ± 9.2 0.006
WPT (°C) 40.0 ± 3.7 41. 2 ± 4.8 0.38
CIP (°C) 8.0 ± 8.5 8.0 ± 7.7 0.81
WIP (°C) 47.0 ± 2.5 47.1 ± 2.8 0.622
Autonomic neuropathy measures
DB-HRV (beats/min) 21.0 ± 15.0 19.0 ± 7.0 0.67
LFa/RFa 2.8 ± 2.5 2.7 ± 2.7 0.42
E/I ratio 1.3 ± 0.2 1.2 ± 0.2 0.004
Valsalva ratio 1.6 ± 0.7 1.4 ± 0.5 0.001
30:15 ratio 1.3 ± 0.1 1.1± 0.1 0.0003
Neuropad (%) 62.4 ± 34.0 75.0 ± 31.0 0.47
Nerve conduction studies
SNAP (µV) 11.4 ± 10.9 10.5 ± 11.3 0.75
SNCV (m/s) 43.5 ± 9.0 40.4 ± 7.4 0.02
PNAP (mV) 3.8 ± 1.9 3.5 ± 1.9 0.299
PMNCV (m/s) 43.5 ± 3.6 42.4 ± 4.3 0.03
Corneal confocal microscopy
CNFD (no./mm2) 28.8 ± 6.5 25.6 ± 5.2 0.03
CNBD (no./mm2) 67.6 ± 30.2 43.7 ± 19.0 < 0.0001
CNFL (mm/mm2) 22.2 ± 4.9 16.1 ± 3.6 < 0.0001
Skin biopsy
IENFD (no./mm) 6.6 ± 4.3 5.2 ± 3.7 0.04
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patients with T2DM was associated with an improvement in corneal nerve fibres, neurophysiology and vibration 
perception over 4 years and correlated with a reduction in  HbA1c34.
Studies have also shown an association between CCM and LDIflare in healthy control  subjects35 and with 
LDIflare, cooling detection thresholds and HRV in patients with  diabetes16. In the present study CCM measures 
worsened with greater magnitude than IENFD and large fibre (VPT, CPT, sural and peroneal nerve conduction 
velocities) and autonomic (E/I ratio, Valsalva ratio and 30:15 ratio) measures of neuropathy. The worsening of 
corneal nerve fibre measures was associated with worsening of other small fibre measures including cold percep-
tion threshold, IENFD and autonomic neuropathy, but not neurophysiology. Indeed, a number of studies have 
shown corneal nerve loss in patients with diabetic autonomic  neuropathy36–38 and a correlation between CCM 
and a wide range of other measures of neuropathy including peroneal and sural nerve  conduction36 and both 
cold and warm perception  thresholds16,39.
Figure 1.  Representative images from skin biopsies from healthy control (A) and diabetes patient of similar age 
at baseline (B) and a follow-up visit after 6.5 years (C). Note numerous branching nerves reaching top layers of 
epidermis (A; red arrows) and sparse short single nerve and two dividing nerves (red arrows) in epidermis of 
the baseline biopsy (B) and more difficult to discern shorter nerves in the follow-up biopsy (red arrows). Scale 
bar for A–C = 100 µm.
Figure 2.  Corneal confocal microscopy image from a healthy control (A) and patient with diabetes at baseline 
(B) and follow-up (C) showing a progressive loss of nerve fibres (red arrows main nerves, yellow arrows 
branches) in patients with diabetes.
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Changes in autonomic neuropathy parameters

































Figure 3.  Percentage change from baseline values in CCM parameters (A), neuropathy symptoms (B), NCV 
and IENFD (C), quantitative sensory testing (D) and autonomic neuropathy (E,F).
Table 3.  Correlations between percentage change in small fibre pathology and other measures of diabetic 
neuropathy from baseline to follow up. NSP—neuropathy symptom profile, NDS—neuropathy disability score, 
DNS—diabetic neuropathy symptom score, VPT—vibration perception threshold, CPT—cold perception 
threshold, DB-HRV—deep breathing heart rate variability, LFA/RFA ratio—low frequency area (sympathetic) 
and high frequency area (parasympathetic) ratio, E/I—expiration/inspiration ratio, CNFD—corneal nerve fibre 
density, CNBD—corneal nerve branch density, CNFL—corneal nerve fibre length, IENFD—intraepidermal 
nerve fibre density. Bold values show statistically significant results.
Variable CNBD CNFD CNFL IENFD
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A limitation of this study is the relatively small number of patients assessed at follow up. However, the main 
strength of this study is the comprehensive phenotyping of diabetic neuropathy over 6.5 years, enabling a detailed 
comparison of the change in small and large fibre measures of diabetic neuropathy.
In conclusion, CCM identifies progressive nerve damage despite an improvement in glycaemic control and 
LDL cholesterol. Furthermore, corneal nerve loss was associated with a loss of IENFD and worsening of other 
measures of small fibre neuropathy. CCM is a rapid, non-invasive test to identify progression of neuropathy and 
may have greater utility than symptoms, signs, QST and nerve conduction studies in longitudinal follow-up 
studies and clinical trials of DPN.
Methods
Participant selection. Nineteen patients with diabetes [type 1 DM (n = 15) and type 2 DM (n = 4)], from 
the Manchester University Hospital Diabetes Centre and 19 age-matched healthy control participants were 
recruited and assessed between 2009 and 2011 and at follow up in 2017. The control group comprised of healthy 
volunteers without DM and were not on any regular medications for any co-morbidities. Patients with a history 
of neuropathy from any other cause, ocular disease, corneal trauma or surgery, systemic disorders affecting the 
skin or cornea were excluded. All the tests performed at baseline were repeated in the follow up study using 
the same protocol and equipment. This study has approval from the Health Research Authority (HRA), North 
West—Greater Manchester South Research Ethics Committee. Written informed consent was obtained from all 
individuals prior to participation. This research adhered to the tenets of the declaration of Helsinki.
Anthropometric and laboratory measurements. All participants underwent assessment of height, 
weight and body mass index (BMI). Glycated haemoglobin (HbA1c), total cholesterol, low-density lipopro-
tein (LDL)-cholesterol, triglycerides (TG), serum creatinine and urinary albumin creatinine ratio (ACR) were 
measured using routine laboratory methods in the Department of Biochemistry, Manchester University NHS 
Foundation Trust. Estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modifi-
cation of Diet in Renal Disease (MDRD) equation: 186 × (creatinine/88.4) − 1.154 × (age) − 0.203 × (0.742 in 
females) × (1.210 if Afro-Caribbean race).
Assessment of neuropathy. The neuropathy symptom profile (NSP) was used to assess the symptoms 
of neuropathy. The modified neuropathy disability score (NDS) which is comprised of an assessment of vibra-
tion perception, pinprick, temperature sensation and presence or absence of ankle reflexes was used to evaluate 
neurological deficits. A Horwell Neurothesiometer (Scientific Laboratory Supplies, Wilford, Nottingham, UK) 
was used to establish the Vibration Perception Threshold (VPT). Cold (CT) and warm (WT) perception thresh-
olds and cold (CIP) and warm induced pain (WIP) thresholds were tested on the dorsolateral aspect of left foot 
using the TSA-II NeuroSensory Analyser (Medoc, Ramat-Yishai, Israel). Electrodiagnostic nerve conduction 
studies (NCS) were undertaken using a Dantec Keypoint System (Dantec Dynamics, Bristol, UK), equipped 
with a DISA temperature regulator to keep the limb temperature constant at 32–35 °C. The ANX 3.0 autonomic 
nervous system monitoring device (ANSAR Medical Technologies, Philadelphia, PA, USA) was used to assess 
deep breathing heart rate variability (DB-HRV), sympathovagal balance via the sympathetic low frequency area 
(LFa)/parasympathetic respiratory frequency area (RFa) ratio, expiratory/inspiratory (E/I ratio), Valsalva ratio 
and 30:15 ratio. Sudomotor dysfunction was assessed by quantifying the percentage colour change after applying 
the Neuropad to the area over the base of the first metatarsal head using our previously established protocol and 
automated  quantification40.
Skin biopsy. Local anaesthetic (1% lignocaine) was applied to the dorsum of the foot, 2 cm above the second 
metatarsal head and two 3 mm punch biopsies were performed. Sections of 50 µm were stained using anti-human 
PGP 9.5 antibody (Abcam, Cambridge, UK). SG chromogen (Vector Laboratories, Peterborough, UK) was used 
to demonstrate nerve fibres and IENFD was quantified using previously established criteria and expressed as the 
number per millimetre length of  epidermis41. The follow-up skin biopsy was taken from the same foot, in close 
proximity to the first biopsy. IENFD was quantified by the same investigator in a masked fashion.
Corneal confocal microscopy (CCM). CCM examination (Heidelberg Retinal Tomography III Rostock 
Cornea Module; Heidelberg Engineering, Heidelberg, Germany) was performed using our previously estab-
lished  protocol42. Six non-overlapping images, three per eye, were selected from the centre of the cornea. Three 
corneal nerve parameters were quantified: Corneal nerve fibre density (CNFD): the total number of major 
nerve fibres per square millimetre of corneal tissue, corneal nerve fibre branch density (CNBD): the number of 
branches emanating from the major nerve trunks per square millimetre of corneal tissue and corneal nerve fibre 
length (CNFL): the total length of all nerve fibres and branches (millimetre per square millimetre) using manual 
quantification software [CCMetrics (Manchester, UK)]43.
Statistical analyses. Statistical analyses were performed using GraphPad Prism for Mac OS X (version 
8.3.0, GraphPad Software, San Diego, California USA, www.graph pad.com). Data were tested for normality 
using the Shapiro–Wilk normality test. All data are expressed as mean ± standard deviation (SD). Continuous 
variables were compared between baseline and follow up visits using the paired t-test for normally distrib-
uted data and Wilcoxon matched-pairs signed rank test for non-normally distributed data. Ordinary one-way 
ANOVA was performed (Kruskal–Wallis test was used for non-normally distributed data) to compare between 
group differences of controls and baseline patient values. Post-hoc corrections for multiple comparison testing 
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was done using Tukey’s test. Correlations were performed between the percentage change in IENFD and CCM 
parameters and other variables using Pearson’s or Spearman’s Rank Test according to the distribution of the data. 
A two-way p-value of less than 0.05 was considered to be statistically significant.
Data availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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